Włodzimierz Mazur

Włodzimierz Mazur

Auto-generated profile, based on publicly available information

Włodzimierz Mazur

Clinical Department of Infectious Diseases in Chorzów, Medical University of Silesia, 40-055, Katowice, Poland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2021 in Liver International
Verified
Journal Article
Closed access
PDF file
AKAleksandra Berkan Kawinska
Aleksandra Berkan Kawinska
APAnna Piekarska
Anna Piekarska
EJEwa Janczewska
Ewa Janczewska
BLBeata Lorenc
Beata Lorenc
MTMagdalena Tudrujek-Zdunek
Magdalena Tudrujek-Zdunek
Robert FlisiakRobert Flisiak
Robert Flisiak

7 November 2023 in Antiviral Research
Verified
Journal Article
Open access
Dorota Zarębska-MichalukDorota Zarębska-Michaluk
Dorota Zarębska-Michaluk
Robert FlisiakRobert Flisiak
Robert Flisiak
EJEwa Janczewska
Ewa Janczewska
HBHanna Berak
Hanna Berak
WMWłodzimierz Mazur
Włodzimierz Mazur
Piotr RzymskiPiotr Rzymski
Piotr Rzymski
The study aimed to assess the phenomenon of achieving sustained virologic response (SVR) in patients with detectable ribonucleic acid (RNA) of hepatitis C virus (HCV) at the end of treatment (ET) with direct-acting antivirals (DAA), find how this is affected by the type of regimen, and how patients experiencing this differed from non-responders with detectable HCV RNA at the ET. The study included all consecutive patients with detectable HCV RNA at the ET selected from the EpiTer-2 database, a retrospective national multicentre project evaluating antiviral treatment in HCV-infected patients in 2015-2023. Of the 16106 patients treated with IFN-free regimens with available HCV RNA assessment at the ET and at follow-up 12 weeks after treatment completion (FU), 1253 (7.8%) had detectable HCV RNA at the ET, and 1120 of them (89%) finally achieved SVR. This phenomenon was significantly more frequent in pangenotypic regimens, 10.3% vs. 4.7% in genotype-specific options (p < 0.001), and the highest proportion was documented for glecaprevir/pibrentasvir (13.7%), and velpatasvir/sofosbuvir ± ribavirin (6.9%). Patients ET + FU- treated with these two pangenotypic regimens (n = 668) had less advanced liver disease, were less frequently infected with genotype (GT) 3, and were significantly more likely to be treatment-naïve than 61 non-responders. We documented 7.8% rate of patients with detectable HCV RNA at the ET, of whom 89% subsequently achieved SVR, significantly more frequently in the population treated with pangenotypic regimens. Less severe liver disease, more often GT3 infection, and a higher percentage of treatment-naive patients distinguished this group from non-responders.

17 February 2016 in Hepatology International
Verified
Journal Article
Closed access
PDF file
EGEdward J. Gane
Edward J. Gane
RRRégine Rouzier
Régine Rouzier
THTarek Hassanein
Tarek Hassanein
CSCatherine A. Stedman
Catherine A. Stedman
WMWlodzimierz Mazur
Wlodzimierz Mazur
JTJames Thommes
James Thommes

1 June 2022 in Polish Journal of Microbiology
Verified
Journal Article
Open access
PDF file
JIJoanna Iwanicka
Joanna Iwanicka
TITomasz Iwanicki
Tomasz Iwanicki
MKMarcin Kaczmarczyk
Marcin Kaczmarczyk
WMWłodzimierz Mazur
Włodzimierz Mazur
Sciendo provides publishing services and solutions to academic and professional organizations and individual authors. We publish journals, books, conference proceedings and a variety of other publications.